The Science Behind Using Circulating Tumor DNA for MCC

In this second part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, explains the data behind the clinical trials on using circulating tumor DNA for merkel cell carcinoma (MCC). She expands on her talk from the 2022 American Academy of Dermatology Annual Meeting.

Related Videos
Related Content

POLL: What Type of Sunscreen Do You Recommend to Your Patients?

May 25th 2023

The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition

March 26th 2022

SCALE 2023 Recap: Day 5

May 21st 2023

The Cutaneous Connection: Episode 27- Benzene Contamination Update

July 22nd 2021

Topical Carboxytherapy and Human Platelet Extract Used as Peri-Procedural Adjuvant Following Non-Ablative Laser Resurfacing

May 21st 2023

Laying Down the Law of Cosmetic Procedures With David Goldberg, MD, JD

May 21st 2023

POLL: What Type of Sunscreen Do You Recommend to Your Patients?

May 25th 2023

The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition

March 26th 2022

SCALE 2023 Recap: Day 5

May 21st 2023

The Cutaneous Connection: Episode 27- Benzene Contamination Update

July 22nd 2021

Topical Carboxytherapy and Human Platelet Extract Used as Peri-Procedural Adjuvant Following Non-Ablative Laser Resurfacing

May 21st 2023

Laying Down the Law of Cosmetic Procedures With David Goldberg, MD, JD

May 21st 2023

POLL: What Type of Sunscreen Do You Recommend to Your Patients?

May 25th 2023

The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition

March 26th 2022

SCALE 2023 Recap: Day 5

May 21st 2023

The Cutaneous Connection: Episode 27- Benzene Contamination Update

July 22nd 2021

Topical Carboxytherapy and Human Platelet Extract Used as Peri-Procedural Adjuvant Following Non-Ablative Laser Resurfacing

May 21st 2023

Laying Down the Law of Cosmetic Procedures With David Goldberg, MD, JD

May 21st 2023
© 2023 MJH Life Sciences

All rights reserved.